Drug Trial News

RSS

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reports a financial update as of June 30, 2010. In addition, the Company provides a progress update of its MARINE and ANCHOR trials, the two on-going Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

10 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three and six months ended June 30, 2010.

10 Aug 2010

Pharmasset third-quarter net loss increases to $16.0 million

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2010.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma Inc. today reported financial results for the fourth quarter and full year of fiscal 2010.

10 Aug 2010

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Elan Corporation, plc and Transition Therapeutics, Inc today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer's disease who received study drug for up to 18 months (Study AD201). Study subjects with MMSE scores between 16 and 26 received ELND005 oral doses of 250 mg, 1000 mg or 2000 mg twice daily or matching placebo. The study's cognitive (NTB) and functional (ADCS-ADL) co - primary endpoints did not achieve statistical significance.

10 Aug 2010

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

Medivation, Inc. today provided a corporate update and reported its financial results for the second quarter ended June 30, 2010.

10 Aug 2010

NIH begins human clinical testing for dengue virus vaccine

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

10 Aug 2010

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.

10 Aug 2010

ACADIA second-quarter net loss decreases to $4.3 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Poniard second-quarter net loss decreases to $6.5 million

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2010. The Company also announced new initiatives to reduce its annual expenditures ("burn rate") by focusing its efforts on existing products and on supporting current and future strategic partnerships. All currency figures reported in this press release, including comparative figures, are in Canadian dollars, unless otherwise specified.

9 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

QRxPharma Limited announced today positive results of its Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of its IV (intravenous) formulation of morphine plus oxycodone versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. The main findings demonstrated that QRxPharma's formulation of MoxDuo IV resulted in fewer side effects and offered better pain relief than morphine alone.

9 Aug 2010

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a clinical study report for its Phase II/III study of azficel-T for the treatment of moderate to severe acne scars to the U.S. Food & Drug Administration (FDA).

9 Aug 2010

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Intellect Neurosciences, Inc announced that it has received a Notice of Allowance from the Canadian Patent and Trademark Office for a new patent related to OX1 (OXIGON™), the Company's clinical-stage drug candidate that has disease-modifying potential for Alzheimer's and other neurodegenerative disorders. OX1 is an orally-administered, brain-penetrating, naturally-occurring, copper-binding small molecule targeting multiple mechanisms that contribute significantly to the underlying pathology of Alzheimer's disease.

9 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

9 Aug 2010

Drug Trial News

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Transcept Pharmaceuticals second-quarter net loss decreases to $2.06 million

Pharmasset third-quarter net loss increases to $16.0 million

Synta second-quarter net loss increases to $9.1 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Elan and Transition Therapeutics report results of ELND005 Phase 2 study for Alzheimer's disease

Medivation net loss decreases from $8.9M in second-quarter 2010 to $7.2M in second-quarter 2011

NIH begins human clinical testing for dengue virus vaccine

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

ACADIA second-quarter net loss decreases to $4.3 million

Poniard second-quarter net loss decreases to $6.5 million

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

Isis second-quarter pro forma net operating loss increases to $15.5 million

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Intellect Neurosciences receives Notice of Allowance for new OXIGON patent in Canada

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant prostate cancer

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News